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Abstract
Research has been conducted to identify sequence polymorphisms of gene promoter regions in patients and control
subjects, including normal individuals, and to determine the influence of these polymorphisms on transcriptional reg-
ulation in cells that express wild-type or mutant p53. In this study we isolated genomic DNA from whole blood of
healthy Japanese individuals and sequenced the promoter regions of the MDM2, p53, and p16
INK4a genes. We identi-
fied polymorphisms comprising 3 nucleotide substitutions at exon 1 and intron 1 regions of the MDM2 gene and 1 nu-
cleotide insertion at a poly(C) nucleotide position in the p53 gene. The Japanese individuals also exhibited p16
INK4a
polymorphismsatseveralpositions,includingposition-191.Reportergeneanalysisbyusingluciferaserevealedthat
the polymorphisms of MDM2, p53, and p16
INK4a differentially altered luciferase activities in several cell lines, including
the Colo320DM, U251, and T98G cell lines expressing mutant p53. Our results indicate that the promoter sequences
of these genes differ among normal Japanese individuals and that polymorphisms can alter gene transcription activ-
ity.
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Introduction
Different populations exhibit sequence polymor-
phisms of the murine double minute 2 (MDM2) gene
(Atwaletal.,2007),atargetgeneofthetranscriptionfactor
p53. A promoter polymorphism of the MDM2 gene,
SNP309,islocatedintheintron1regionofthegeneandin-
fluences transcriptional regulation in a cell line expressing
wild-type p53 (Bond et al., 2004). Non-cancerous control
subjects frequently have a polymorphism of p53 at codon
72 (Wu et al., 1995; Minaguchi et al., 1998), and this com-
mon polymorphism differentially alters promoter activity
of the MDM2 gene that contains the SNP309 polymor-
phism (Yang et al., 2007). Cytosine-phospho-guanine
(CpG) dinucleotides are methylated by DNA methyltrans-
ferase (DNMT) (Siedlecki and Zielenkiewicz, 2006), and
the methylated form interacts with methyl-CpG-binding
proteins (Fan and Hutnick, 2005), which serve as modula-
torsofgenetranscription.CpGmethylationinthepromoter
region of p53 decreases promoter activity of the gene
(SchroederandMass,1997).GenomicDNAobtainedfrom
blood of people exposed to arsenic has been reported to ex-
hibit methylation at the promoter regions of p53 and
p16
INK4a, a cycline-dependent kinase inhibitor, and the
DNA methylation status of these promoters differs among
people (Chanda et al., 2006). Normal populations have
polymorphisms in DNMT; a polymorphism DNMT3L af-
fects the ability of this gene to stimulate DNA methylation
(El-Maarrietal.,2009).Nucleotidesubstitutionsinthep53
promoter at 4 mutated positions, including position -250,
and in the p16
INK4a promoter at positions -735, -493, and
-191 are found not only in Taiwanese patients with uterine
leiomyoma (Hsieh et al., 2007) and frequently in mela-
noma families from other populations (Harland et al.,
2000) but also in control groups; p53 promoter polymor-
phism at position -250 and p16
INK4a promoter polymor-
phism at position -191 are located within CpG dinucleo-
tides.Thus,controlsubjects,includingnormalpopulations,
exhibit gene promoter polymorphisms. However, no stud-
ies have investigated differences at other nucleotide posi-
tions in MDM2, p53, and p16
INK4a promoter sequences
among healthy individuals. In addition, it has not been de-
termined whether known polymorphisms in the promoter
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Research Articlesequenceofthesegenesarepresentinothernormalpopula-
tions and alter gene promoter activity in other cell lines.
A number of polymorphisms have been identified in
10 ENCODE (Encyclopedia of DNA Elements) regions in
the human genome of 48 individuals from 4 populations,
including 8 Japanese individuals. Moreover, the frequency
distributions of these polymorphisms have been investi-
gated among different populations (International HapMap
Consortium, 2005). In the present study, we sequenced the
MDM2 and p53 promoters and the p16
INK4a promoter nu-
cleotides at positions -735, -493, and -191 from genomic
DNA extracted from whole blood samples obtained from
healthyJapaneseindividualsanddeterminedwhetherthese
promoter polymorphisms affect gene promoter activity in
cell lines expressing mutant or wild-type p53. We found
that normal Japanese individuals exhibit polymorphisms in
these regions of the MDM2, p53, and p16
INK4a genes and
that these polymorphisms alter promoter activity in some
cell lines.
Materials and Methods
Extraction of genomic DNA
Human peripheral blood was obtained from 17
healthy Japanese students, who consented to have their
DNA sequenced for identification of polymorphisms.
Genomic DNA was extracted from whole blood by using a
QIAamp DNA Blood Mini kit (Qiagen, Hilden, Germany).
DNA analysis of the samples showed that the frequency of
commonly known polymorphisms (Kadowaki et al., 1995;
Eguchi-Ishimae et al., 2005) was similar to that previously
identified in control Japanese subjects.
Amplification of promoter regions by polymerase
chain reaction
Promoter sequences of the MDM2 genes were ampli-
fied by polymerase chain reaction (PCR) in a reaction mix-
turecontaininggenomicDNA(0.1g)andMDM2primers
(Table 1) in the presence or absence of 5% dimethyl
sulfoxide with DNA polymerase (KOD-Plus DNA poly-
merase (Takagi et al., 1997); Toyobo, Osaka, Japan) ac-
cording to the manufacturer’s instructions. The amplifica-
tion was performed in a thermal cycler (Takara PCR
thermal cycler MP; Takara, Osaka, Japan) under the fol-
lowingconditions:denaturationat94°Cfor15s,annealing
at (melting temperature [Tm]-5) °C for 30 s, and extension
at 68 °C for 2 min. p53 and p16
INK4a promoter sequences
were amplified using p53 and p16
INK4a primers (Table 1)
and DNA polymerase (PfuTurbo DNA polymerase (Cline
et al., 1996); Stratagene, La Jolla, CA) according to the
manufacturer’s instructions under the following condi-
tions:denaturationat94°Cfor30s,annealingat(Tm-5)°C
for 1 min, and extension at 72 °C for 2 min.
Determination of nucleotide sequences
Sequence reactions were performed using an ABI
PRISM Dye Terminator Cycle Sequencing kit (Perkin-
Elmer Biosystems, Foster City, CA), and nucleotide se-
quences were determined using the ABI PRISM 377 auto-
mated DNA sequencer (Perkin-Elmer Biosystems).
Construction of reporter plasmid vectors
Regions from positions -725 to +99 of the MDM2
gene, positions -920 to +184 of the p53 gene, and positions
-1703 to -93 of the p16
INK4a gene were amplified by PCR
with primers bearing a cleavage site of the restriction en-
zymeKpnIorBglII.Theamplifiedfragmentsweredigested
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Table 1 - Primers used for PCR and sequencing
Primer position Oligonucleotide primer
MDM2 gene
-725 to -704 5’-TCTGACCGAGATCCTGCTGCTT-3’
-465 to -442 5’-TCTATCGCTGGTTCCCAGCCTCTG-3’
-310 to -289 5’-TTCGGACGGCTCTCGCGGCGGT-3’
+96 to +75 5’-AAGCTACAAGCAAGTCGGTGCT-3’
-725 to -702 5’-TATTGGTACCTCTGACCGAGATCCTGCTGCTTTC-3’
+99 to +76 5’-TAGTAGATCTCTAAAGCTACAAGCAAGTCGGTGC-3’
p53 gene
-918 to -899 5’-GCTGGGAGTTGTAGTCTGAA-3’
-669 to -690 5’-CATTGTTGTATTCCTGAGTGCC-3’
-584 to -564 5’-GTGATAAGGGTTGTGAAGGAG-3’
-518 to -495 5’-GGGTGTGGATATTACGGAAAGCCT-3’
-233 to -210 5’-ACTTGCCCTTACTTGTCATGGCGA-3’
-221 to -240 5’-AGTAAGGGCAAGTAATCCGC-3’
+184 to +161 5’-AGGTCTCCCAACAATGCAACTCCT-3’
-920 to -898 5’-TACTGGTACCCTGCTGGGAGTTGTAGTCTGAAC-3’
+184 to +161 5’-TAGTAGATCTAGGTCTCCCAACAATGCAACTCCT-3’
p16
INK4a gene
-2028 to -2009 5’-TACCTCCTTGCGCTTGTTAT-3’
-1706 to -1684 5’- ATGTTGGTCAGGCTTGTCTCGAA-3’
-1173 to -1192 5’-TGCCACACATCCTAAGCTAA-3’
-1198 to -1174 5’-CAGGTATTAGCTTAGGATGTGTGGC-3’
-950 to -931 5’-CTGGTCTAGGAATTATGACT-3’
-485 to -465 5’-TGTATCGCGGAGGAAGGAAAC-3’
-475 to -498 5’-TCCGCGATACAACCTTCCTAACTG-3’
-381 to -361 5’-AGGGAGGCCGGAGGGCGGTGT-3’
-248 to -228 5’-TGCCACATTCGCTAAGTGCT-3’
+214 to +194 5’-CTGCAAACTTCGTCCTCCAGA-3’
-1703 to -1683 5’-ATAGGTACCTTGGTCAGGCTTGTCTCGAAC-3’
-93 to -113 5’-CATAGATCTTCCTCTTTCTTCCTCCGGTGC-3’
PGV-B2 vector
-59 to -40 5’-CTAGCAAAATAGGCTGTCCC-3’
+112 to +91 5’-CTTTATGTTTTTGGCGTCTTCC-3’
Nucleotide positions have been numbered by considering the positions of
nucleotideCatthe5’endofexon2(Zaubermanetal.,1995)intheMDM2
gene (accession number: U39736.1), nucleotide G (accession number:
X54156.1)inthep53gene(TuckandCrawford,1989),nucleotideAatthe
initiation site for translation in the p16
INK4a gene (Hara et al., 1996), and
nucleotide G at the KpnI site of the PGV-B2 vector (sequence identical to
that of pGL3-basic vector; GenBank accession number, U47295) as +1.
The underlines indicate the recognition sites of the KpnI (singlet) and
BglII (doublet) restriction enzymes.and separated by agarose gel electrophoresis. DNA frag-
ments were extracted using a gel extraction kit (Concert
Gel Extraction System; Invitrogen, Carlsbad, CA), precipi-
tated with ethanol, and ligated between the KpnI and BglII
sites of the PicaGene Basic Vector 2 (PGV-B2) reporter
plasmid (Nippon Gene, Tokyo, Japan). The constructed
vectors were cloned in Escherichia coli DH5 (Toyobo)
and then purified using a QIAfilter Plasmid Midi kit (Qia-
gen). Nucleotide sequences were confirmed using primers
(Table 1), including the PGV-B2 vector primers.
Analysis of nucleotide sequences and
polymorphisms
The nucleotide sequences obtained for 17 individuals
(or 9 individuals in the case of p16
INK4a) were compared
with DNA sequences (accession numbers U39736.1,
U28935.1, X54156.1, J04238.1, M13111.1, U94788.1,
AF022809, and X94154.1) in the DNA database GenBank
at the National Center for Biotechnology Information by
using the program BLAST (basic local alignment search
tool). For detection of polymorphisms, nucleotides were
compared among individuals by using the sequence align-
ment editor program BioEdit.
Cell culture
Human colon adenocarcinoma Colo320DM (Ameri-
can Type Culture Collection [ATCC], Manassas, VA) and
breastcarcinomaYMB-1(JapaneseCollectionofResearch
Bioresources [JCRB], Osaka, Japan) cell lines were grown
in RPMI 1640 medium (Nissui Pharmaceutical, Tokyo, Ja-
pan). The human glioma U251 (Riken Cell Bank [RCB],
Tsukuba, Japan) cell line was grown in Dulbecco’s modi-
fiedEagle’smedium(NissuiPharmaceutical).Humanglio-
blastomaT98GandcervixepithelioidcarcinomaHeLacell
lines (RCB) were cultured in Eagle’s minimum essential
medium (Nissui Pharmaceutical) containing nonessential
amino acids and sodium pyruvate (Invitrogen). These cells
weregrownat37°Cinmediasupplementedwith10%fetal
bovine serum (Trace Scientific, Melbourne, Australia) in a
humidified atmosphere of 95% air and 5% CO2.
Transfection and reporter gene analysis
The cultured cells were plated at a density of 1.04 x
10
4cells/cm
2andthentransfectedwith1 gofvectorDNA
using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’sinstructions.Thetransfectedcellswerecul-
tured and then lysed after 24 h in a reporter lysis buffer
(Promega,Madison,WI).Luciferasewasusedasareporter
gene, and luciferase activity was determined using the Lu-
ciferaseAssaySystem(Promega)inaluminometer(Mono-
light 2010; Analytical Luminescence Laboratory, San
Diego, CA). For correction of variations in the amount of
vector DNA incorporated into cells, the cultured cells were
co-transfected with pCMV (Clontech, Palo Alto, CA), a
-galactosidase expression vector. Luciferase activity was
normalized according to the -galactosidase activity.
Statistical analysis
Comparisonsamongmultiplegroupswereperformed
using analysis of variance (ANOVA) with a post hoc test.
Differences between two groups were evaluated using un-
paired Student’s t test. Statistical significance was defined
as p < 0.01.
Results
Polymorphisms in promoter regions of the MDM2,
p53, and p16
INK4a genes
We amplified the regions containing MDM2 and p53
promoters (Tuck and Crawford, 1989; Zauberman et al.,
1995) in genomic DNA isolated from 17 healthy individu-
als by PCR and determined the nucleotide sequences of the
amplified regions. Comparisons of the nucleotide se-
quences among individuals revealed that nucleotide A was
substituted with nucleotide G at position -628 in exon 1
(Figure 1A) and C with T at -466 (Figure 1B) and T with G
at -215 (Figure 1C) in intron 1 of the MDM2 gene. Nucleo-
tide C was inserted at positions -824 to -818 (C-to-C inser-
tion) of the p53 gene (Figure 2). We identified 9 genotypes
related to MDM2 and p53 polymorphisms containing nu-
cleotide alterations (I-IX; Table 2); genotypes I, II, III, VI,
and VIII were observed in 1 individual each, types V and
IX were observed in 2 individuals each, and types IV and
VII were observed in 4 individuals each. Promoter nucleo-
tides of the p16
INK4a gene at positions -735, -493, and -191
were examined using samples obtained from 9 individuals
randomly selected from the 17 Japanese individuals. We
observed substitution of nucleotide A with nucleotide G in
p16
INK4a at position -191 (Figure 3); no nucleotide substitu-
tions were observed at positions -735 and -493. This nucle-
otide alteration was observed in 3 individuals who were
homozygous A/A, 4 individuals who were heterozygous
A/G,and2individualswhowerehomozygousG/Gat-191.
The polymorphic MDM2, p53, and p16
INK4a se-
quences were cloned into PGV-B2 vectors, and 3 con-
structs of MDM2 PGV-ACT, PGV-ACG, and PGV-GTT
(Table 3), 2 constructs of p53 PGV-7C and PGV-8C
(Table 4), and 2 constructs of p16
INK4a PGV-A (containing
nucleotide A at -191) and PGV-G (containing nucleotide G
at -191) were obtained. Each of the cloned sequences was
consistent with the nucleotide sequences determined by di-
rectly sequencing the PCR products (Figure 4E and other
datanotshown).Inconfirmationoftheclonedsequencesof
p16
INK4a,wealsoobserved2allelesofp16
INK4acontaininga
substitution of nucleotide C with T at position -1602 (Fig-
ure 4A), and substitutions of C with T at -871 (Figure 4B),
T with A at -315 (Figure 4D), and A with G at -191 (Figure
4E) and deletion of nucleotide C at positions -862 to -858
(Figure 4C). These nucleotide alterations at positions
Polymorphisms in normal individuals 617-1602, -871, -862 to -858, and -315 were ascertained by di-
rect sequencing of PCR products (Figure S1). The MDM2
nucleotides at positions -339, -333, and -218 and positions
-237 to -234, -231 to -228, and -223 to -221 (G-to-G inser-
tion) and the p53 nucleotides at positions -512 to -511
(G-to-G deletion) and -479 to -477 (T-to-T insertion) dif-
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Figure 1 - Promoter polymorphisms of MDM2 at positions -628, -466, and -215. (A-C) Genomic DNA was amplified by PCR with a forward primer at
positions -725 to -704 and a reverse primer at +96 to +75 of the MDM2 gene, and nucleotide sequences were determined by directly sequencing the PCR
products. These sequencing reactions were performed using primers at positions -725 to -704 and -310 to -289. (*) shows nucleotides at positions -628
(A),-466(B),and-215(C)intheMDM2promoters,where“N”indicatesheterozygousnucleotides.Nucleotidesaroundthesepositions(*)areindicated.
Figure2-Apoly(C)polymorphismofp53atpositions-824to-818.(A-C)GenomicDNAwasamplifiedbyPCRwithaforwardprimeratpositions-918
to -899 and a reverse primer at -669 to -690 of the p53 gene. Nucleotide sequences were determined by directly sequencing the PCR products; these se-
quencing reactions were performed using a primer at positions -918 to -899. (*) shows homozygous (A and C) or heterozygous (B) nucleotides at posi-
tions -824 to -818 in the p53 promoters, where “NNCN” in (B) indicates sequences including “GCCG” and “CGCC,” which result from nucleotide C in-
sertion. Nucleotides around the poly(C) polymorphic position (*) are indicated.
Figure 3 - A polymorphism of p16
INK4a at position -191. Genomic DNA was amplified by PCR with a forward primer at positions -485 to -465 and a re-
verseprimerat+214to+194ofthep16
INK4agene,andnucleotidesequencesweredeterminedbydirectlysequencingthePCRproducts.Thesesequencing
reactions were performed using a primer at positions -248 to -228. (*) shows nucleotides at position -191 in the p16
INK4a promoters, where “N” indicates
heterozygous nucleotides. Nucleotides around the polymorphic position (*) are indicated.feredfromthenucleotidesatthecorrespondingpositionsin
the MDM2 and p53 sequences deposited in the GenBank
database (accession numbers U39736.1, U28935.1,
X54156.1, J04238.1, and M13111.1) (Tables 3 and 4).
However, these nucleotides were identical among all study
individuals (Tables 3 and 4). The p53 nucleotides at posi-
tions -512 to -511 (G-to-G deletion) and -479 to -477
(T-to-T insertion) in the healthy individuals were consis-
tentwiththecorrespondingnucleotidesinthep53sequence
intheGenBankdatabase(accessionnumberU94788.1,Ta-
ble 4).
Influence of promoter polymorphisms on reporter
gene activity in different cell lines
Several cell lines, including the colo320DM, U251,
and T98G cell lines, were transfected with vector con-
structs containing MDM2, p53, and p16
INK4a poly-
morphisms, and the activity of the luciferase reporter gene
in the transfected cells was examined to assess whether
these polymorphisms alter gene promoter activity. The
levelofluciferaseactivityincreasedincelllinestransfected
with the MDM2 construct PGV-ACT (containing nucleo-
tidesAatposition-628,Cat-466,andTat-215)(Figure5);
slight luciferase activity was detected in cell lines trans-
fected with the empty vector PGVB2 (PGV-(-)). A signifi-
cant decrease or increase was found in the luciferase
activity of Colo320DM or U251 cells transfected with the
MDM2 construct PGV-GTT (containing an A-to-G substi-
tution at -628 and a C-to-T substitution at -466) compared
to the activity in cells transfected with PGV-ACT (Figure
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Table 3 - MDM2 promoter sequences in vector constructs.
Position from the 5’ end of exon 2 in the MDM2 gene
Type -628 -466 -413 -339 -333 -237 to -234 -231 to -228 -223 to -221 -218 -215
U39736.1 A C N A C 4G 4G 3G G T
U28935.1 ------- 3 G C G
PGV-ACT A C C G G 5G 5G 4G C T
PGV-ACG A C C G G 5G 5G 4G C G
PGV-GTT G T C G G 5G 5G 4G C T
MDM2 promoter regions were ligated to PGV-B2 vectors, and the ligated nucleotides were examined using primers at positions -725 to -704, -465 to
-442, and -310 to -289. U39736.1 and U28935.1 represent sequences obtained from GenBank.
Table 4 - p53 promoter sequences in vector constructs.
Position from nucleotide G in the p53 gene
Type -824 to -818 -512 to -511 -479 to -477
X54156.1 7C GG 3T
J04238.1 - GG 3T
M13111.1 - GG 3T
U94788.1 7C G 4T
PGV-7C 7C G 4T
PGV-8C 8C G 4T
p53 promoter regions were ligated to PGV-B2 vectors, and the ligated nu-
cleotides were examined using primers at positions -918 to -899, -584 to
-564,and-518to-495.X54156.1,J04238.1,M13111.1,andU94788.1are
sequences obtained from GenBank.
Table2-MDM2andp53promoterpolymorphismsinnormalindividuals.
Polymorphic position in the promoter regions of genes
MDM2 gene p53 gene
Individual
genotype
-628 -466 -215 -824 to -818
I A/A C/C T/T 7C/8C
II A/A C/C T/G 7C/7C
III A/A C/C T/G 7C/8C
IV A/A C/C G/G 7C/8C
V A/A C/C G/G 8C/8C
VI A/G C/T T/T 7C/7C
VII A/G C/T T/T 7C/8C
VIII A/G C/T T/G 7C/7C
IX G/G T/T T/T 7C/7C
Figure 4 - Nucleotides in the vector constructs of p16
INK4a at positions
-1602, -871, -862 to -858, -315, and -191. (A-E) Genomic DNA was am-
plified by PCR with a forward primer at positions -1703 to -1683 and a re-
verse primer at -93 to -113 of the p16
INK4a gene and then cloned into
PGVB2 vectors. The nucleotides of the cloned sequences were examined
using primers at positions -1706 to -1684, -950 to -931, -381 to -361, and
-248 to -228. (*) shows nucleotides at positions -1602 (A), -871 (B), -862
to -858 (C), -315 (D), and -191 (E) of the p16
INK4a promoters. Nucleotides
around these polymorphic positions (*) are indicated.5A, B). Similar increase in luciferase activity was also ob-
served in YMB-1 (Figure 5D) or HeLa (data not shown)
cells transfected with the PGV-GTT construct. The MDM2
construct PGV-ACG (containing a T-to-G substitution at
-215) did not significantly alter luciferase activity in the
transfectedColo320DMandU251cells(Figure5A,B)and
increased the activity in the transfected YMB-1 cells (Fig-
ure 5D). PGV-ACT, PGV-ACG, and PGV-GTT T98G
transfectants had similar luciferase activities (Figure 5C).
In the case of Colo320DM, U251, and T98G cells, the luci-
feraseactivitiesofcellstransfectedwithp53PGV-8C(con-
taining nucleotide C insertion) and cells transfected with
p16
INK4a PGV-G were significantly lower and higher than
the activities of cells transfected with p53 PGV-7C and
cells transfected with p16
INK4a PGV-A, respectively (Fig-
ures 6 and 7). The p53 PGV-8C and p16
INK4a PGV-G vec-
tors did not decrease and increase the luciferase activity in
the transfected YMB-1 and HeLa cells, respectively (data
not shown).
Discussion
In the present study, we found that normal Japanese
individuals exhibit polymorphisms in the MDM2, p53, and
p16
INK4a promoter regions (Figures 1-4 and Figure S1) and
that these individuals harbor several nucleotides in the
MDM2 and p53 promoters that are different from those in
the GenBank database (Tables 3 and 4); however, these nu-
cleotides were identical among all the Japanese individuals
included in this study. This result implies that the MDM2
and p53 promoter nucleotides differ among different popu-
lations, including individuals within the same population.
The frequency of SNP309, a polymorphism involving nu-
cleotide G, in intron 1 of the MDM2 gene is low among Af-
rican Americans and high in other populations (Dharel et
al., 2006; Hu et al., 2006; Millikan et al., 2006; Park et al.,
2006; Atwal et al., 2007), including Ashkenazi Jewish,
White, and Japanese populations. The polymorphism that
we identified at position -215 in the intronic MDM2 pro-
moter was polymorphism SNP309 of MDM2. The G allele
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Figure 5 - Effects of MDM2 polymorphisms on luciferase activity in different cell lines. (A-D) Colo320DM (A), U251 (B), T98G (C), and YMB-1 (D)
cells were transfected with the indicated vector constructs of PGV-(-), PGV-ACT, PGV-ACG, and PGV-GTT. The transfected cells were cultured for
24h,andluciferaseactivitywasdetermined.DataareshownaspercentagesofvaluesobtainedfromthePGV-ACTtransfectantsandareexpressedasthe
mean  SEM (n = 8) (A-D). *: Significant difference compared with the PGV-ACT transfectant.frequency of SNP309 at -215 in our Japanese samples was
high (44.1%; 15 of 34 alleles) and similar to that in healthy
individuals who visited a Japanese hospital (54%; 52 of 96
alleles) (Dharel et al., 2006). African Americans, Cauca-
sians,andAshkenaziJewishpopulationshaveotherMDM2
polymorphisms involving nucleotide substitutions from A
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Figure 6 - Effects of the p53 poly(C) polymorphism on luciferase activity
in different cell lines. (A-C) Colo320DM (A), U251 (B), and T98G (C)
cells were transfected with the indicated vector constructs of PGV-(-),
PGV-7C, and PGV-8C. The transfected cells were cultured for 24 h, and
luciferase activity was determined. Data are shown as percentages of val-
ues obtained from the PGV-7C transfectants and are expressed as the
meanSEM(n=8).*:SignificantdifferencecomparedwiththePGV-7C
transfectant.
Figure 7 - Effects of the p16
INK4a polymorphism at position -191 on luci-
ferase activity in different cell lines. (A-C) Colo320DM (A), U251 (B),
and T98G (C) cells were transfected with the indicated vector constructs
of PGV-(-), PGV-A, and PGV-G. The transfected cells were cultured for
24 h, and luciferase activity was determined. Data are shown as percent-
ages of values obtained from the PGV-A transfectants and are expressed
as the mean  SEM (n = 8). *: Significant difference compared with the
PGV-A transfectant.to G (rs937283) and C to T (rs2870820), which are regis-
teredinthedbSNPdatabase,atratesof27%,34%,and25%
and of 6%, 34%, and 0%, respectively (Atwal et al., 2007).
Thesepolymorphismsarelocatedatposition-628inexon1
(rs937283) and position -466 in intron 1 (rs2870820) of the
MDM2 gene and corresponded to the nucleotides observed
inoursamples.ThefrequencyoftheGorTalleleinhealthy
Japanese individuals was 29.4% each (10 of 34 alleles).
TheTallelefrequencyinJapaneseindividuals(29.4%)was
higher than that in African American (6%) and Ashkenazi
Jewish (0%) populations. Families with Li-Fraumeni (LF;
an autosomal dominant cancer-predisposition syndrome)
andLF-likefamiliesexhibitanucleotidedeletioninthep53
promoter (Attwooll et al., 2002), and mutations have been
identified at 15 positions in the p53 promoter in Taiwanese
patients with uterine leiomyoma (Hsieh et al., 2007). The
nucleotide deletion (position -342) and 4 mutations (posi-
tions -250, -216, -103, and -33) within 15 positions have
also been observed in control subjects at rates of 0.3%
(Attwooll et al., 2002) and 1.8%-4% (Hsieh et al., 2007),
respectively. These polymorphisms were not observed in
our healthy Japanese samples, and the poly(C) polymor-
phism of p53 at positions -824 to -818 (C-to-C insertion)
found in our samples was observed at a high frequency of
41.2% (14 of 34 alleles). It has been reported that the nu-
cleotides at positions -735, -493, and -191 of p16
INK4a are
substituted not only in melanoma families in the United
Kingdom, the United States, Italy, and Australia but also
frequently in control populations (Harland et al., 2000). In
these control populations, the frequencies of homozygous
A/A, heterozygous A/G, and homozygous G/G
polymorphisms at position -191 of p16
INK4a are 38%, 48%,
and 14%, respectively (Harland et al., 2000). The corre-
sponding frequencies of these polymorphisms in our sam-
ples were 33.3%, 44.4%, and 22.2%. In addition, the
frequency of polymorphisms C/C, C/C, 5C/5C, and T/T at
positions -1602, -871, -862 to -858, and -315 of p16
INK4a
was 44.4%; that of C/C, C/T, 5C/4C, and T/A was 22.2%;
that of C/C, T/T, 4C/4C, and A/A was 22.2%; and that of
C/T, C/C, 5C/5C, and T/T was 11%. Thus, the promoter
polymorphismsinMDM2atpositions-215,-628,and-466,
in p53 at positions -342, -250, -216, -103, and -33, and in
p16
INK4a at positions -735, -493, and -191 were differen-
tially distributed in some normal and control populations.
Inthisstudy,polymorphismswereobservedamonghealthy
Japanese individuals in the sequence of MDM2 at positions
-628 and -466, of p53 at positions -824 to -818, and of
p16
INK4a at positions -1602, -871, -862 to -858, -315, and
-191.
The promoter region of MDM2 includes multiple
transcription-factor response elements (Phelps et al., 2003;
Bond et al., 2004), including the p53-responsive element
(positions -93 to -74 and -55 to -36) (Zauberman et al.,
1995). Reporter gene activity is increased in wild-type
p53-expressing HeLa cells transfected with the G allele of
MDM2 SNP309 (Bond et al., 2004); the polymorphism
SNP309 is located adjacent to a binding site of the tran-
scription factor SP1 in the MDM2 promoter and can alter
SP1bindingatthissite.TheMDM2GalleleofSNP309ob-
served at -215 similarly increased reporter activity in HeLa
cells (data not shown) and YMB-1 cells (Figure 5D). In
contrast, the reporter luciferase activity of Colo320DM,
U251,andT98GcellstransfectedwithSNP309at-215was
not altered (Figure 5A, B, C). We also observed a decrease,
increase, or no change in luciferase activity in transfected
Colo320DM, T98G, U251, HeLa, or YMB-1 cells that har-
bored the MDM2 polymorphism at both positions -628 and
-466 (Figure 5). Deletion of a promoter region of MDM2 at
positions -725 to -311, which include the -628 and -466
polymorphic positions, did not alter luciferase activity in
Colo320DM cells and increased luciferase activity in other
cells (Figure S2). This deletion experiment indicated that
luciferase activity in Colo320DM cells may not be regu-
lated constitutively by transcription factors through the
MDM2 promoter sequence containing the polymorphic
sites -628 and -466 and that luciferase activity in other cells
appears to be negatively regulated by these factors via the
promoter containing the polymorphic sites. The reporter
gene activity induced by polymorphism is thought to be
caused by cell type-dependent regulation of the promoter
machinery. A search for transcription factors that can bind
to sequences around the polymorphic sites was carried out
in the TRANSFAC database by using the MatInspector
program (Wingender et al., 2000). Database analysis
showed that the -466 MDM2 polymorphism affected the
matrix similarity of the transcription factor MZF1. The
MDM2 polymorphism at both positions -628 and -466 may
alter promoter activity via a known regulatory factor at po-
sition -466.
Patients with diseases such as cancer show not only
nucleotide deletions and mutations (Pollock et al., 2001;
Attwooll et al., 2002; Taniai et al., 2002; Fombonne et al.,
2005; Hsieh et al., 2007) but also nucleotide methylation
(Hermanetal.,1996;Narimatsuetal.,2004;Amatyaetal.,
2005) in the promoter regions of p53 and p16
INK4a. The de-
letion at positions -346 to -338 (C/EBP site) of p53 in LF
(Attwooll et al., 2002) and the mutation at position -250 of
p53 in patients with uterine leiomyoma (Hsieh et al., 2007)
are located within CpG dinucleotides. The locus of the p53
poly(C) polymorphism at positions -824 to -818 was adja-
cent to CpG sequences, which are located at positions -826
to -825 and -818 to -817, and the -191 nucleotide G of
p16
INK4a was located within CpG sites. Methylation of the
p16
INK4a promoter has been found in noncancerous tissues
in 3 of 21 (14%) individuals with non-cirrhotic virus-
positivelivers(Narimatsuetal.,2004).Exposuretoarsenic
differentially stimulates the methylation of p53 and
p16
INK4a promoters (Chanda et al., 2006). We did not ob-
servenucleotidealterationsinthesemethylatednucleotides
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Some transcription factors interact with p53 and
p16
INK4a promoters and regulate gene promoter activity
throughthesepromoterregions(Furlongetal.,1996;Kirch
et al., 1999; Myöhänen and Baylin, 2001; Xue et al., 2004;
Wu et al., 2007). The polymorphic sites identified in these
promotersinthepresentstudywerenotlocatedwithintheir
transcription factor-binding sites. Promoter methylation of
p53 is induced in the T98G cell line, and expression of the
p53 gene is upregulated by treatment of the cell line with
5-aza-2’-deoxycytidine, a methylation inhibitor, (Amatya
et al., 2005). Luciferase reporter gene activity was altered
in T98G cells harboring the p53 poly(C) polymorphism
(Figure 6C). Chromatin immunoprecipitation with an anti-
body against the methyl-CpG binding domain protein
(MBD) 2, an MBD family protein (Hendrich and Bird,
1998), revealed that the MBD2 complexes extracted from
human colon cell lines bind to the p16
INK4a promoter region
(from position -494 to -101) and that this binding is abol-
ished by treatment with the methylation inhibitor 5-aza-2’-
deoxycytidine (Magdinier and Wolffe, 2001). It was also
revealed that although HeLa cells express MBD2 (Billard
et al., 2002), MBD2 does not bind to the p16
INK4a promoter
region (Magdinier and Wolffe, 2001). Database analysis
with the TFSEARCH program showed that several tran-
scription factors, including those of SP1, CREB, and
NF-B, can bind to the p53 poly(C) and p16
INK4a -191 sites
and that nucleotide alterations at these sites affect the simi-
larity of sequences of the substrates for the transcription
factors activator protein 2 and ATF or NF-B, etc., respec-
tively. The regions around and within the p53 poly(C) se-
quence are rich in guanine and cytidine nucleotides and are
similar in part to the consensus sequences for transcription
factors such as activating enhancer-binding protein 2 (Hil-
ger-Eversheim et al., 2000) whose gene includes the p53-
responsive sequence (Li et al., 2006). p53 can form com-
plexes with SP1, CREB-binding protein, and NF-B pro-
tein (Borellini and Glazer, 1993; Huang et al., 2007). The
p53 poly(C) and p16
INK4a -191 polymorphisms did not de-
crease and increase luciferase activity in the YMB-1 and
HeLa cells expressing wild-type p53, respectively. In con-
trast, these polymorphisms altered luciferase activity in the
Colo320DM, U251, and T98G cells (Figures 6 and 7) that
harboredp53mutantsatpositionscodon248,273,and237,
respectively. In each case, the polymorphism-induced re-
porter gene activity seems to be attributable to cellular dif-
ferences in promoter regulation that occurs through the
binding of DNA-interacting proteins; the regulation may
result in a decrease or increase in reporter activity and may
depend on cellular methylation of CpG nucleotides and on
the ability of transcription factors.
Patients with cancers exhibit differential MDM2 and
p53 protein expression in gliomas and breast cancers,
which contain the G and/or T alleles of SNP309 (Tsuiki et
al., 2007; Krekac et al., 2008), and differential p16
INK4a
protein expression in gastric cancers in the absence of
methylation (Tsujie et al., 2000). Gene expression analysis
performed using the TCGA database revealed that MDM2
and p16
INK4a gene expression levels differ among patients
with cancers, including those with glioblastoma multi-
forme; it is not known whether the regulatory regions of
these genes have polymorphisms. Chemotherapeutic drugs
increase the transcript level of p53 target genes in cells ex-
pressing wild-type MDM2, and the increased levels de-
crease in cells expressing the SNP309 G allele (Arva et al.,
2005). In addition, MDM2 promoter activity is increased
through the p53-binding site in the MDM2 gene in cells ex-
pressing the thyroid hormone receptor (Qi et al., 1999) and
through multiple transcription-factor response elements in
estrogen receptor (ER) -positive breast cancer cells
(Phelps et al., 2003), and p16
INK4a reporter activity is in-
creased in senescent cells in comparison with that in young
cells (Wang et al., 2001). Breast cancer YMB-1 and cervix
epithelioidcarcinomaHeLacelllinesareER-positiveand
-negative cells, respectively. The region around the MDM2
polymorphic site at position -466 was a possible binding
site of the transcription factor GATA (Phelps et al., 2003)
whose gene expression is increased in ER-positive cells
treated with estradiol (Eeckhoute et al., 2007). The normal
Japanese individuals who participated in our study in-
cluded 13 male and 4 female students. Further studies are
needed to clarify the significance of promoter polymor-
phisms in the variations in gene expression among individ-
uals, in responses to chemical and hormone stimuli in
individualsofdifferentgendersandages,andundernormal
and aberrant conditions.
Research has been conducted on the construction of
common patterns of sequence variations in the human ge-
nome(InternationalHapMapConsortium,2005).Polymor-
phism SNP309 is present in linkage disequilibrium with
other MDM2 intronic polymorphisms, and the linkage dif-
fers between different populations: Ashkenazi Jewish and
Caucasian populations or African Americans (Atwal et al.,
2007). Exon 1 of the p14
ARF gene (Robertson and Jones,
1998) is located approximately 20 kb upstream of the first
p16
INK4a exon 1 and splices into the common exons 2 and 3
shared with p16
INK4a in a different reading frame (Mao et
al., 1995). A Korean population has a promoter polymor-
phism of p14
ARF at position -1477, which is observed in
strong linkage disequilibrium in a haplotype block, and the
-1477 A allele of p14
ARF is associated with the methylation
status of the p14
ARF promoter and alters the level of p14
ARF
mRNA in colorectal tumor tissues (Kang et al., 2008). Jap-
anese populations frequently exhibited p14
ARF polymor-
phism at position -1477 (Figure S3). p16
INK4a polymor-
phisms at positions -871, -862 to -858, and -315 or MDM2
polymorphisms at positions -628 and -466 appeared to be
possible candidates for linkage disequilibrium. Single-nu-
cleotide polymorphisms (SNPs) (Brookes, 1999) are the
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tion and are associated with a predisposition to disease and
susceptibilityortolerancetomedication.Theyareusefulas
markers of individual constitution and as information for
personalized medicine. A population-based study showed
that the SNP309 polymorphism in MDM2 and/or the com-
mon polymorphism at codon 72 in p53 are associated with
predispositions to carcinomas in populations who visited
Asian hospitals (Kawaguchi et al., 2000; Hong et al., 2005;
Dharel et al., 2006). Other studies showed that the MDM2
SNP309 polymorphism or the p53 common polymorphism
atcodon72isnotassociatedwithoronlyweaklyassociated
with predisposition to carcinomas in other populations
(Millikanetal.,2006;Krekacetal.,2008;Torneselloetal.,
2009; Zubor et al., 2009). The p16
INK4a -191 polymorphism
does not segregate with disease in melanoma kindreds in
the United Kingdom (Harland et al., 2000). It is of interest
to determine whether the promoter polymorphisms of
MDM2, p53, and p16
INK4a identified in this study are pres-
ent in linkage disequilibrium in a haplotype block and in-
fluence predisposition to diseases; our findings provide in-
formation for studies on the construction of common
polymorphism patterns and for studies on the frequency
distribution among different populations, including dis-
eased patients. In the current study, we identified promoter
polymorphisms in healthy Japanese individuals and found
that gene promoter activity was altered by these
polymorphisms in different cell lines. Our results indicate
that promoter sequences of the MDM2, p53, and p16
INK4a
genes differ among normal Japanese individuals.
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